Purpose of this Study
We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
- Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
- Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
- Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.
Study Details
Full Title
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00113811
NCT ID
NCT05868629
Phase
IV
Enrollment Status
OPEN TO ACCRUAL